Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Key Points

• Bimekizumab demonstrated favourable efficacy across most assessed outcomes at Week 48-52, indicating long-term benefits.
• This systematic review highlights promising results that support bimekizumab as a viable treatment for hidradenitis suppurativa.
• Analysis included various clinical outcomes to compare bimekizumab with other approved biologics for HS.
• These findings suggest potential clinical implications for managing moderate-to-severe hidradenitis suppurativa effectively.